日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)

皮疹剂量:一线厄洛替尼治疗晚期非小细胞肺癌患者的 II 期试验——东部肿瘤协作组研究 (E3503)

Brahmer, J R; Lee, J W; Traynor, A M; Hidalgo, M M; Kolesar, J M; Siegfried, J M; Guaglianone, P P; Patel, J D; Keppen, M D; Schiller, J H

SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15

SULF2甲基化是肺癌生存的预后指标,并通过诱导ISG15增加对拓扑异构酶I抑制剂的敏感性。

Tessema, M; Yingling, C M; Thomas, C L; Klinge, D M; Bernauer, A M; Liu, Y; Dacic, S; Siegfried, J M; Dahlberg, S E; Schiller, J H; Belinsky, S A

HGF-independent potentiation of EGFR action by c-Met.

c-Met 对 EGFR 作用的 HGF 非依赖性增强作用

Dulak A M, Gubish C T, Stabile L P, Henry C, Siegfried J M

Topographic analysis of K- ras mutations in histologically normal lung tissues and tumours of lung cancer patients

对组织学正常的肺组织和肺癌患者肿瘤中K-ras突变进行地形学分析

Keohavong, P; Mady, H H; Gao, W M; Siegfried, J M; Luketich, J D; Melhem, M F